Tesamorelin — dosage, half-life & reference guide

Growth hormone peptide · also known as Egrifta

The only GH peptide currently FDA-approved (for HIV lipodystrophy). Tesamorelin specifically targets visceral fat — the deep abdominal fat that wraps around organs and drives metabolic dysfunction. Produces meaningful reductions in belly fat while improving body composition.

Commonly-researched dose ranges

Tesamorelin is commonly researched at 1–2 mg, daily, by SubQ injection. These are reference ranges from the literature and community use, not a prescription.

Half-life

Estimated half-life: ~26 min. See how it accumulates in the half-life calculator.

Safety & interactions

Commonly reported effects: injection site reaction, fluid retention, joint pain, nausea, glucose dysregulation. Discuss with your clinician.

Open the full Tesamorelin guide (needs JavaScript). PepVault is a private research and tracking tool, not medical advice.